Core Viewpoint - MediPharm Labs Corp. is set to release its third quarter financial results for the period ending September 30, 2025, on November 13, 2025, before market opening [1] Group 1: Financial Results Announcement - The company will host a conference call and webcast on November 13, 2025, at 10:00 a.m. Eastern time to discuss its financial results [2] - Participants are encouraged to dial in approximately 15 minutes before the start of the call [3] Group 2: Company Overview - Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates and advanced derivative products [5] - The company operates a Good Manufacturing Practices certified facility with ISO standard-built clean rooms, focusing on delivering pure and precision-dosed cannabis products [5] - In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in North America with a commercial-scale domestic GMP License for the extraction of multiple natural cannabinoids [6] - In 2023, MediPharm acquired VIVO Cannabis Inc., expanding its reach to medical patients in Canada, Australia, and Germany [7]

Core Viewpoint - MediPharm Labs Corp. has received a recommendation from Glass Lewis to support its nominees for the Board of Directors in the upcoming shareholder meeting on June 16, 2025 [1][2] Group 1: Shareholder Voting - Glass Lewis is the second independent proxy advisory firm to recommend voting for the Company's nominees, following a similar recommendation from ISS [2] - MediPharm urges shareholders to vote using the GREEN proxy to support all nominees and resolutions, with votes due by 3:00 p.m. Eastern time on June 13, 2025 [3] - Shareholders are encouraged to contact their broker for their control number to ensure their vote is counted [4] Group 2: Company Overview - Founded in 2015, MediPharm Labs specializes in the development and manufacture of pharmaceutical-quality cannabis concentrates and products [5] - The company received a Pharmaceutical Drug Establishment License from Health Canada in 2021, making it the only North American company with a commercial-scale GMP License for cannabinoid extraction [6] - In 2023, MediPharm acquired VIVO Cannabis Inc., expanding its reach to medical patients in Canada, Australia, and Germany [7]

Core Viewpoint - MediPharm Labs Corp. has successfully removed all conditions precedent related to the sale of its Hope Facility to Rubicon Organics Inc. for $4.5 million, which is expected to close in June 2025, enhancing the company's cash position and maintaining its virtually debt-free status [1][2][3]. Financial Impact - The $4.5 million proceeds from the sale will support MediPharm's strategy to deliver long-term value for shareholders and partners, focusing on international growth and acquisition opportunities [3]. - Since the implementation of its cost-reduction strategy in Q2 2022, MediPharm has reduced operating and overhead costs by approximately $42 million annually [4]. Asset Management - The Hope Facility was acquired during the VIVO Cannabis Inc. acquisition in 2023, and all commercial activities at this facility ceased in 2024, consolidating operations at other facilities to reduce costs [3]. - The total value of asset sales since 2022, including the Hope Facility, amounts to approximately $14 million, contributing to cost reduction and strengthening the balance sheet [3]. Company Overview - MediPharm Labs, founded in 2015, specializes in the development and manufacture of pharmaceutical-quality cannabis concentrates and products, operating under Good Manufacturing Practices [5]. - The company holds a Pharmaceutical Drug Establishment License from Health Canada, making it the only North American company with a commercial-scale GMP license for extracting multiple natural cannabinoids [6]. - The acquisition of VIVO Cannabis Inc. in 2023 expanded MediPharm's reach to medical patients in Canada, Australia, and Germany [7].